<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39410827</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2532-5264</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace</Title><ISOAbbreviation>Monaldi Arch Chest Dis</ISOAbbreviation></Journal><ArticleTitle>The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4081/monaldi.2024.3070</ELocationID><Abstract><AbstractText>COVID-19 has a negative impact on the survival of respiratory patients, especially those with interstitial lung disease. This review aims to better understand the effect of COVID-19 on patients with idiopathic pulmonary fibrosis (IPF). A systematic search of MEDLINE, PubMed, Embase, and Scopus performed from December 2019 up to July 2024 identified relevant studies. Eligibility criteria included English language, sample size â‰¥10 patients, COVID-19 infection and outcome measures. Two independent reviewers assessed studies using the Newcastle-Ottawa Scale for bias and extracted data. Meta-analysis employed a random-effects model, and the Grading of Recommendations Assessment, Development and Evaluation assessed evidence quality. Outcomes considered were hospitalization, intensive care unit admission, and mortality. Of the 1541 initially identified articles, 6 high-quality studies were included. Meta-analysis revealed a 34% mortality rate [95% confidence interval (CI): 21-48%], 36% hospitalization rate (95% CI: 10-75%), and 31% ICU admission rate (95% CI: 7-71%) among IPF patients with COVID-19. The certainty of evidence was low or very low due to publication bias and heterogeneity. This study underscores the elevated risk of hospitalization and death in IPF patients with COVID-19, emphasizing the vulnerability of this population. Prompt and tailored care is crucial to mitigate the impact of COVID-19 on IPF patients, necessitating proactive measures, vaccination, and comprehensive management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cavasin</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pneumology, Fondazione IRCCS San Gerardo dei Tintori, Monza; School of Medicine and Surgery, University of Milano-Bicocca, Milan. d.cavasin@campus.unimib.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanini</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Pneumology, Fondazione IRCCS San Gerardo dei Tintori, Monza; School of Medicine and Surgery, University of Milano-Bicocca, Milan. u.zanini@campus.unimib.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montelisciani</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Milan; Bicocca Bioinformatics Biostatistics and Bioimaging Center, Vedano al Lambro (MB). laura.montelisciani@unimib.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valsecchi</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Milan; Bicocca Bioinformatics Biostatistics and Bioimaging Center, Vedano al Lambro (MB). grazia.valsecchi@unimib.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabbri</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Imperial National Institute of Health Research Biomedical Research Center, National Heart and Lung Institute, Imperial College London; Interstitial Lung Disease Unit, Royal Brompton Hospital, Guys and St Thomas' NHS Trust, London. l.fabbri@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antolini</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Milan; Bicocca Bioinformatics Biostatistics and Bioimaging Center, Vedano al Lambro (MB). laura.antolini@unimib.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luppi</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pneumology, Fondazione IRCCS San Gerardo dei Tintori, Monza; School of Medicine and Surgery, University of Milano-Bicocca, Milan. fabrizio.luppi@unimib.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Monaldi Arch Chest Dis</MedlineTA><NlmUniqueID>9307314</NlmUniqueID><ISSNLinking>1122-0643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>3</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39410827</ArticleId><ArticleId IdType="doi">10.4081/monaldi.2024.3070</ArticleId></ArticleIdList></PubmedData></PubmedArticle>